Pharmacogenomics of Stimulant Treatment Response
Recruiting
Observational Study
Attention-Deficit/ Hyperactivity Disorder (ADHD)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 6 – 24
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- University of Calgary · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients will be eligible for participation if all the following are true.
* Aged 6 - 24 years.
* Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
* Primary diagnosis of ADHD (all types).
* Starting Methylphenidate (excluding immediate releas…
Contacts